Literature DB >> 14711072

Obesity and pharmacologic therapy.

Marie Thearle1, Louis J Aronne.   

Abstract

Obesity is a chronic, complex, multifactorial disorder with increasing prevalence in modern society. Lifestyle modification has had limited success in treating this disorder. Currently approved pharmacologic treatments for obesity include sibutramine and orlistat, which have been associated with significantly greater weight loss than that seen with dieting alone. In addition, a greater percentage of patients who receive medical treatment achieve weight losses of more than 5% to 10% of their initial body weight. This weight loss is associated with improvements in blood pressure, insulin sensitivity, and dyslipidemia. Multiple new therapies that target several different regulatory pathways are currently in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711072     DOI: 10.1016/s0889-8529(03)00066-5

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

Review 1.  Current and novel approaches to the drug therapy of obesity.

Authors:  Jean-Philippe Chaput; Angelo Tremblay
Journal:  Eur J Clin Pharmacol       Date:  2006-08-26       Impact factor: 2.953

2.  Clinical strategies for managing the overweight neurology patient.

Authors:  Lawrence J Cheskin; Carmine M Sonzone; Lisa M Davis
Journal:  Neurol Clin Pract       Date:  2012-03

3.  Efficacy of a meal replacement diet plan compared to a food-based diet plan after a period of weight loss and weight maintenance: a randomized controlled trial.

Authors:  Lisa M Davis; Christopher Coleman; Jessica Kiel; Joni Rampolla; Tammy Hutchisen; Laura Ford; Wayne S Andersen; Andrea Hanlon-Mitola
Journal:  Nutr J       Date:  2010-03-11       Impact factor: 3.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.